4 results match your criteria: "China. pzjzml1980@taihehospital.com.[Affiliation]"
Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
Sci Rep
April 2024
Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, Hubei, 442000, China.
RAB3B is essential for the transportation and secretion within cells. Its increased expression is linked to the development and progression of various malignancies. However, understanding of RAB3B's involvement in carcinogenesis is mostly limited to specific cancer subtypes.
View Article and Find Full Text PDFTRIP6 a potential diagnostic marker for colorectal cancer with glycolysis and immune infiltration association.
Sci Rep
February 2024
Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for precision Diagnosis and Treatment of liver cancer, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Article Synopsis
- - TRIP6 is an adaptor protein involved in signaling related to colorectal cancer (CRC), but its exact role, especially concerning glucose metabolism and immune cell infiltration, is not well understood.
- - Research using RNA sequencing data shows that TRIP6 is significantly overexpressed in CRC, correlating with disease stage and poor survival rates, and is linked to processes like glycolysis and tumor promotion.
- - The study suggests that TRIP6's expression influences immune cell dynamics and angiogenesis in tumors, highlighting its potential as a biomarker and therapeutic target for CRC treatment.
DARS2 overexpression is associated with PET/CT metabolic parameters and affects glycolytic activity in lung adenocarcinoma.
J Transl Med
August 2023
Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, China.
Background: This study investigated the correlation between the expression of DARS2 and metabolic parameters of F-FDG PET/CT, and explored the potential mechanisms of DARS2 affecting the proliferation and glycolysis of lung adenocarcinoma (LUAD) cells.
Methods: This study used genomics and proteomics to analyze the difference in DARS2 expression between LUAD samples and control samples. An analysis of 62 patients with LUAD who underwent F-FDG PET/CT examinations before surgery was conducted retrospectively.
eIF6 is potential diagnostic and prognostic biomarker that associated with F-FDG PET/CT features and immune signatures in esophageal carcinoma.
J Transl Med
July 2022
Department of Nuclear Medicine and Institute of Anesthesiology and Pain, and Department of Pathology, Taihe Hospital, Hubei University of Medicine, No. 32, Renmin Road, Shiyan, 442000, China.
Background: Although eukaryotic initiation factor 6 (eIF6) is a novel therapeutic target, data on its importance in the development of esophageal carcinoma (ESCA) remains limited. This study evaluated the correlation between eIF6 expression and metabolic analysis using fluorine-18 fluorodeoxyglucose (F-FDG) -Positron emission tomography (PET) and immune gene signatures in ESCA.
Methods: This study employed The Cancer Genome Atlas (TCGA) to analyze the expression and prognostic value of eIF6, as well as its relationship with the immune gene signatures in ESCA patients.